Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025Therapeutic Advances in Medical OncologyOpen Access

Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMarine LejeuneEWEric WasielewskiVLVincent Leroy

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows no survival advantage of pembrolizumab-chemotherapy over pembrolizumab in aggressive non-small-cell lung cancer with PDL1 ≥50%.

Key Points

  • Overall survival was not improved with pembrolizumab-CT compared to pembrolizumab in patients with advanced non-small-cell lung cancer.
  • Among patients receiving pembrolizumab-CT, there was a significant decrease in restricted mean survival time by 7.9 months compared to those on pembrolizumab.
  • Analysis included advanced non-small-cell lung cancer patients with PDL1 ≥50% and ECOG scores of 0-1, assessing various tumor characteristics.
  • Findings suggest increased hospitalizations related to toxicities were more frequent with pembrolizumab-CT, indicating potential adverse effects on clinical outcomes.

Cite This Study

Lejeune et al. (2025) studied this question.

synapsesocial.com/papers/6930e8e3ea1aef094cca3fe1https://doi.org/10.1177/17588359251396266
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study.2025
  2. 2Pembrolizumab in the treatment of non-small cell lung cancer—experiences from clinical practice2025 · 3 citations
  3. 3Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%)2025
  4. 4First real-world experience with 1L pembrolizumab and chemotherapy treatment for advanced triple-negative breast cancer in Poland: safety analysis and first survival outcomes from a multicenter cohort2025
  5. 5Predictors of outcomes in advanced non-small cell lung cancer treated with pembrolizumab maintenance.2025